Literature DB >> 12077693

A particular case with long-term follow-up of rare malignant hemangiopericytoma of the lung with metachronous diaphragmatic metastasis.

P P Brega Massone1, C Lequaglie, B Conti, F Ferro, B Magnani, I Cataldo.   

Abstract

The authors report the case of a woman with a primary hemangiopericytoma of the lung and successive metachronous diaphragmatic metastasis treated with surgery only according to the patient's decision. The patient was first submitted to left lower lobectomy with resection of diaphragm and three ribs en-bloc for pulmonary sarcoma. One year later, a chest computed tomography (CT) scan showed a small lesion above the diaphragm on the left side. She refused the proposed operation and returned fifteen months later with a new thorax CT, and told us that she had in the meantime become pregnant and given birth. A rethoracotomy to remove the metastatic diaphragmatic tumor was performed. Chemotherapy with anthracycline and iphosphamide was proposed, but the patient again refused therapy for fear of side effects impairing another pregnancy. Currently, the patient is alive and disease-free, 68 months after the first treatment. The authors emphasize the long-term follow-up obtained with surgery alone in this kind of rare sarcoma.

Entities:  

Mesh:

Year:  2002        PMID: 12077693     DOI: 10.1055/s-2002-32407

Source DB:  PubMed          Journal:  Thorac Cardiovasc Surg        ISSN: 0171-6425            Impact factor:   1.827


  2 in total

1.  Metastatic recurrence of an intracranial hemangiopericytoma 8 years after treatment: report of a case with emphasis on the role of PET/CT in follow-up.

Authors:  Nilendu C Purandare; Sumeet G Dua; Bharat Rekhi; Sneha Shah; Anshu R Sharma; Venkatesh Rangarajan
Journal:  Cancer Imaging       Date:  2010-05-08       Impact factor: 3.909

2.  Myopericytoma arising from myopericytosis-a hitherto unrecognized entity within the lung.

Authors:  Ulrike Gruber-Moesenbacher; Alicia Morresi-Hauff; Katja Behr; Helmut Popper
Journal:  Virchows Arch       Date:  2020-11-26       Impact factor: 4.064

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.